Summary | |
---|---|
Symbol | NCR3 |
Name | natural cytotoxicity triggering receptor 3 |
Aliases | 1C7; NKp30; CD337; LY117; MALS; NK-p30; activating NK-A1 receptor; activating natural killer receptor p30; n ...... |
Chromosomal Location | 6p21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cell membrane Single-pass type I membrane protein |
Domain |
PF07686 Immunoglobulin V-set domain |
Function |
Cell membrane receptor of natural killer/NK cells that is activated by binding of extracellular ligands including BAG6 and NCR3LG1. Stimulates NK cells cytotoxicity toward neighboring cells producing these ligands. It controls, for instance, NK cells cytotoxicity against tumor cells. Engagement of NCR3 by BAG6 also promotes myeloid dendritic cells (DC) maturation, both through killing DCs that did not acquire a mature phenotype, and inducing the release by NK cells of TNFA and IFNG which promote DC maturation. |
Biological Process |
GO:0001906 cell killing GO:0001909 leukocyte mediated cytotoxicity GO:0001910 regulation of leukocyte mediated cytotoxicity GO:0001912 positive regulation of leukocyte mediated cytotoxicity GO:0001913 T cell mediated cytotoxicity GO:0001914 regulation of T cell mediated cytotoxicity GO:0001916 positive regulation of T cell mediated cytotoxicity GO:0002228 natural killer cell mediated immunity GO:0002250 adaptive immune response GO:0002347 response to tumor cell GO:0002418 immune response to tumor cell GO:0002420 natural killer cell mediated cytotoxicity directed against tumor cell target GO:0002423 natural killer cell mediated immune response to tumor cell GO:0002443 leukocyte mediated immunity GO:0002449 lymphocyte mediated immunity GO:0002456 T cell mediated immunity GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002697 regulation of immune effector process GO:0002699 positive regulation of immune effector process GO:0002703 regulation of leukocyte mediated immunity GO:0002705 positive regulation of leukocyte mediated immunity GO:0002706 regulation of lymphocyte mediated immunity GO:0002708 positive regulation of lymphocyte mediated immunity GO:0002709 regulation of T cell mediated immunity GO:0002711 positive regulation of T cell mediated immunity GO:0002715 regulation of natural killer cell mediated immunity GO:0002717 positive regulation of natural killer cell mediated immunity GO:0002819 regulation of adaptive immune response GO:0002821 positive regulation of adaptive immune response GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002824 positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002831 regulation of response to biotic stimulus GO:0002833 positive regulation of response to biotic stimulus GO:0002834 regulation of response to tumor cell GO:0002836 positive regulation of response to tumor cell GO:0002837 regulation of immune response to tumor cell GO:0002839 positive regulation of immune response to tumor cell GO:0002855 regulation of natural killer cell mediated immune response to tumor cell GO:0002857 positive regulation of natural killer cell mediated immune response to tumor cell GO:0002858 regulation of natural killer cell mediated cytotoxicity directed against tumor cell target GO:0002860 positive regulation of natural killer cell mediated cytotoxicity directed against tumor cell target GO:0007156 homophilic cell adhesion via plasma membrane adhesion molecules GO:0007157 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0008037 cell recognition GO:0031341 regulation of cell killing GO:0031343 positive regulation of cell killing GO:0031349 positive regulation of defense response GO:0042267 natural killer cell mediated cytotoxicity GO:0042269 regulation of natural killer cell mediated cytotoxicity GO:0042271 susceptibility to natural killer cell mediated cytotoxicity GO:0045088 regulation of innate immune response GO:0045089 positive regulation of innate immune response GO:0045954 positive regulation of natural killer cell mediated cytotoxicity GO:0060370 susceptibility to T cell mediated cytotoxicity GO:0098742 cell-cell adhesion via plasma-membrane adhesion molecules |
Molecular Function |
GO:0050839 cell adhesion molecule binding |
Cellular Component |
GO:0005913 cell-cell adherens junction |
KEGG |
hsa04650 Natural killer cell mediated cytotoxicity |
Reactome |
R-HSA-1280218: Adaptive Immune System R-HSA-168256: Immune System R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell |
Summary | |
---|---|
Symbol | NCR3 |
Name | natural cytotoxicity triggering receptor 3 |
Aliases | 1C7; NKp30; CD337; LY117; MALS; NK-p30; activating NK-A1 receptor; activating natural killer receptor p30; n ...... |
Chromosomal Location | 6p21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between NCR3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between NCR3 and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | NCR3 |
Name | natural cytotoxicity triggering receptor 3 |
Aliases | 1C7; NKp30; CD337; LY117; MALS; NK-p30; activating NK-A1 receptor; activating natural killer receptor p30; n ...... |
Chromosomal Location | 6p21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of NCR3 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | NCR3 |
Name | natural cytotoxicity triggering receptor 3 |
Aliases | 1C7; NKp30; CD337; LY117; MALS; NK-p30; activating NK-A1 receptor; activating natural killer receptor p30; n ...... |
Chromosomal Location | 6p21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of NCR3 in various data sets.
|
Points in the above scatter plot represent the mutation difference of NCR3 in various data sets.
|
Summary | |
---|---|
Symbol | NCR3 |
Name | natural cytotoxicity triggering receptor 3 |
Aliases | 1C7; NKp30; CD337; LY117; MALS; NK-p30; activating NK-A1 receptor; activating natural killer receptor p30; n ...... |
Chromosomal Location | 6p21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NCR3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | NCR3 |
Name | natural cytotoxicity triggering receptor 3 |
Aliases | 1C7; NKp30; CD337; LY117; MALS; NK-p30; activating NK-A1 receptor; activating natural killer receptor p30; n ...... |
Chromosomal Location | 6p21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NCR3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NCR3. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | NCR3 |
Name | natural cytotoxicity triggering receptor 3 |
Aliases | 1C7; NKp30; CD337; LY117; MALS; NK-p30; activating NK-A1 receptor; activating natural killer receptor p30; n ...... |
Chromosomal Location | 6p21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NCR3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | NCR3 |
Name | natural cytotoxicity triggering receptor 3 |
Aliases | 1C7; NKp30; CD337; LY117; MALS; NK-p30; activating NK-A1 receptor; activating natural killer receptor p30; n ...... |
Chromosomal Location | 6p21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of NCR3 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | NCR3 |
Name | natural cytotoxicity triggering receptor 3 |
Aliases | 1C7; NKp30; CD337; LY117; MALS; NK-p30; activating NK-A1 receptor; activating natural killer receptor p30; n ...... |
Chromosomal Location | 6p21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between NCR3 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | NCR3 |
Name | natural cytotoxicity triggering receptor 3 |
Aliases | 1C7; NKp30; CD337; LY117; MALS; NK-p30; activating NK-A1 receptor; activating natural killer receptor p30; n ...... |
Chromosomal Location | 6p21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting NCR3 collected from DrugBank database. |
There is no record. |